Irritation and staining by 10-butyryl dithranol (butantrone) in psoriasis.
An open clinical trial was carried out using butantrone ointment in the treatment of 10 patients with psoriasis in order to assess staining and irritation in relation to efficacy. At 0.5% and 1.0% strengths, butantrone produced significant levels of irritation and staining with minimal clinical response and poor patient compliance.
D000293:Adolescent; D000328:Adult; D000875:Anthralin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*; D013194:Staining and Labeling
D009824:Ointments; C038464:butantrone; D000875:Anthralin